Integra LifeSciences Holdings Corporation
) declared the first successful implantation of its Integra Titan
Reverse Shoulder System in the United States. The system is
designed for effective shoulder replacement surgery, with special
focus on patients who have no other non-operative option as a
The Reverse Shoulder System is built on a unique platform stem,
which simplifies the conversion of a primary total shoulder, or
hemi for fracture, to a reverse shoulder. It reduces the
complexity associated with removing a stem that is otherwise
properly attached to the patient's bone.
The integrated, fully interchangeable components ensure proper
compatibility between all primary, reverse and fracture humeral
bodies and the press-fit or cemented platform stems. This
flexibility facilitates surgeons to conduct minimally invasive
intraoperative procedures, optimizing continued care throughout
the patient's lifetime.
William Geissler, M.D., Professor of Orthopaedic Surgery at the
University of Mississipi Medical Center, conducted the first
implant of the Titan Reverse Shoulder System. He appreciated the
system for its ability to cut down on valuable operative time and
the ease with which he was able to custom fit the prosthesis to
the patient. The instrumentation helped Geissler to place and
orient the prosthesis accurately, making the operative experience
for him a rather pleasant one.
Geissler was examining a patient who already had two prior
attempts at massive cuff repair without any significant relief
from pain and limited mobility. During surgery, it was diagnosed
that the patient's cuff tear was irreparable. Moreover she was
suffering from severe arthritis. These factors were deemed
appropriate for her to undergo reverse shoulder arthroplasty.
It is anticipated that the global shoulder replacement market is
expected to be worth $865 million in 2014 and is further expected
to touch the $1.3 billion mark by 2017. IART is pleased to add
the new Titan Reverse Shoulder System, expanding their portfolio
in the shoulder segment. The successful implantation and the
subsequent positive feedback from the surgeons strengthen the
company's belief that the new system will be able to garner a
healthy market share going forward.
Currently, IART carries a Zacks Rank #3 (Hold). Other stocks in
the medical devices segment that are worth a look include
Gilead Sciences Inc.
), each of which carries a Zacks Rank # 1 (Strong Buy).
AFFYMAX INC (AFFY): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
GILEAD SCIENCES (GILD): Free Stock Analysis
INTEGRA LIFESCI (IART): Free Stock Analysis
To read this article on Zacks.com click here.